Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial

European Heart Journal

Volumn 37, Issue 4, 2016, Pages 400-408

  Magnani, Giulia ^a   Storey, Robert F ^b   Steg, Gabriel ^c,d,e   Bhatt, Deepak L ^a   Cohen, Marc ^f   Kuder, Julia ^a   Im, Kyungah ^a   Aylward, Philip ^g   Ardissino, Diego ^h   Isaza, Daniel ⁱ   Parkhomenko, Alexander ^j   Goudev, Assen R ^k   Dellborg, Mikael ^l   Kontny, Frederic ^m   Corbalan, Ramon ⁿ   Medina, Felix ^o   Jensen, Eva C ^p   Held, Peter ^p   Braunwald, Eugene ^a   Sabatine, Marc S ^a   Bonaca, Marc P ^a   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSERM   (France)

^f RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^g FLINDERS UNIVERSITY   (Australia)

^h UNIVERSITY HOSPITAL OF PARMA   (Italy)

ⁱ FUNDACIÓN CARDIOINFANTIL INSTITUTO DE CARDIOLOGÍA   (Colombia)

^j Ukranian Strazhesko Institute of Cardiology   (Ukraine)

^k UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^l UNIVERSITY OF GOTHENBURG   (Sweden)

^m STAVANGER UNIVERSITY HOSPITAL   (Norway)

ⁿ PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^o HOSPITAL NACIONAL CAYETANO HEREDIA   (Peru)

^p ASTRAZENECA R AND D   (Sweden)

more..

Author keywords

Myocardial infarction; Renal dysfunction; Secondary prevention; Ticagrelor

Indexed keywords

CREATININE; PLACEBO; TICAGRELOR; ADENOSINE; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; THROMBOSIS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

ADENOSINE; AGED; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84960355772     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv482     Document Type: Article

References (18)

1. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 2010;121:357-365.
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA 2007;298: 2038-2047.
3. Dumaine RL, Montalescot G, Steg PG, Ohman EM, Eagle K, BhattDL; REACH Registry Investigators. Renal function, atherothrombosis extent, and outcomes in high-risk patients. Am Heart J 2009;158:141-148.
4. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-1295.
5. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS; The Hemodyalysis (HEMO) Study. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000;58:353-362.
6. Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. Circulation 2012;125:2649-2661.
7. Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, Califf RM, Topol EJ. The efficacy and safety of short-and long-term dual antiplatelet therapy in patients withmild ormoderate chronic kidney disease: results from theClopidogrel for the Reduction of EventsDuringObservation (CREDO) trial. Am Heart J 2008;155:687-693.
8. Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, Fox KA, Montalescot G, Weber MA, Haffner SM, Dimas AP, Steg PG, Topol EJ; CHARISMA Investigators. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] Trial). Am J Cardiol 2009;103:1359-1363.
9. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation 2010;122:1056-1067.
10. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32: 2999-3054.
11. Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van't Hof A, Widimsky P, ZahgerD. ESCguidelines for themanagement of acutemyocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-2619.
12. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-1800.
13. Bonaca MP, Bhatt DL, Braunwald E, Cohen M, Steg PG, Storey RF, Held P, Jensen EC, Sabatine MS. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014;167:437-444.
14. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007;53:766-772.
15. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
16. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(Suppl. 1):S1-S266.
17. Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed 1997;54: 201-208.
18. Vasaiwala S, Cannon CP, Fonarow GC, Peacock WF, Laskey W, Schwamm LH, Liang L, Hernandez AF, Peterson ED, Rosas SE, Bhatt DL; Get with the Guidelines Steering Committee and Investigators. Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program. Clin Cardiol 2012;35:541-547.